65671-54-7

Basic information

• Product Name: (S)-2-[(tert-Butoxycarbonyl)amino]-5-(dimethylamino)pentanoic acid
• Synonyms: (S)-2-[(tert-Butoxycarbonyl)amino]-5-(dimethylamino)pentanoic acid
• CAS NO: 65671-54-7
• Molecular Formula: C₁₂H₂₄N₂O₄
• Molecular Weight: 260.32996
• Mol File: 65671-54-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 400.3±40.0 °C(Predicted)
• Appearance: /
• Density: 1.079±0.06 g/cm3(Predicted)
• PKA: 3.82±0.21(Predicted)
• CAS DataBase Reference: (S)-2-[(tert-Butoxycarbonyl)amino]-5-(dimethylamino)pentanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-[(tert-Butoxycarbonyl)amino]-5-(dimethylamino)pentanoic acid(65671-54-7)
• EPA Substance Registry System: (S)-2-[(tert-Butoxycarbonyl)amino]-5-(dimethylamino)pentanoic acid(65671-54-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 22-26-36/37/39
• Hazardous Substances Data: 65671-54-7(Hazardous Substances Data)

Usage

Description

(S)-2-[(tert-butoxycarbonyl)amino]-5-(dimethylamino)pentanoic acid, commonly known as Boc-Dap(DMAP), is a chemical compound derived from amino acid pentanoic acid with a tert-butoxycarbonyl (Boc) protecting group attached to the amino group. It is utilized in the field of biochemistry and organic synthesis, playing a crucial role in the development of peptide-based pharmaceuticals and drug delivery systems due to its ability to protect and control the reactivity of amino acids during synthesis. Boc-Dap(DMAP) is also instrumental in the synthesis of complex peptides and peptidomimetic molecules, as well as in the study of protein structure and function. Its potential applications extend to the development of antimicrobial and anticancer agents.

Uses

Used in Pharmaceutical Development:
(S)-2-[(tert-butoxycarbonyl)amino]-5-(dimethylamino)pentanoic acid is used as a building block in the development of peptide-based pharmaceuticals for its ability to protect and control the reactivity of amino acids during synthesis, ensuring the formation of desired peptide structures.
Used in Drug Delivery Systems:
In the Drug Delivery Industry, (S)-2-[(tert-butoxycarbonyl)amino]-5-(dimethylamino)pentanoic acid is used as a component in the design of drug delivery systems to enhance the stability and bioavailability of peptide-based therapeutics.
Used in Organic Synthesis:
(S)-2-[(tert-butoxycarbonyl)amino]-5-(dimethylamino)pentanoic acid is used as a reagent in organic synthesis for the synthesis of complex peptides and peptidomimetic molecules, contributing to the development of novel bioactive compounds.
Used in Protein Research:
In the field of Protein Research, (S)-2-[(tert-butoxycarbonyl)amino]-5-(dimethylamino)pentanoic acid is used as a tool in the study of protein structure and function, aiding in understanding the complex interactions and mechanisms of proteins.
Used in Antimicrobial Agents Development:
(S)-2-[(tert-butoxycarbonyl)amino]-5-(dimethylamino)pentanoic acid is used as a precursor in the development of antimicrobial agents, potentially contributing to the creation of new treatments for infectious diseases.
Used in Anticancer Agents Development:
In the Oncology Industry, (S)-2-[(tert-butoxycarbonyl)amino]-5-(dimethylamino)pentanoic acid is used as a starting material in the development of anticancer agents, with potential applications in the treatment of various types of cancer.

Upstream product

• 50-00-0 formaldehyd 
• 2480-93-5 Boc-Orn(Z)-OH 
• 21887-64-9 N₂-(tert-butoxycarbonyl)-L-ornithine 

Downstream Products

• 884049-27-8 [4-tert-butoxycarbonylamino-5-(4-{4-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-tetrahydro-pyran-4-carbonyl}-piperazin-1-yl)-5-oxo-pentyl]-trimethyl-ammonium 

Relevant articles and documents

TGR5 AGONISTS

TGR5 agonists of structural formula VIII(Q), wherein X, R1, R2, and R5 are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

Design and synthesis of novel sulfonamide-containing bradykinin hB 2 receptor antagonists. 2. Synthesis and structure-activity relationships of α,α-cycloalkylglycine sulfonamides

Recently we reported on the design and synthesis of a novel class of selective nonpeptide bradykinin (BK) B2 receptor antagonists (J. Med. Chem. 2006, 3602-3613). This work led to the discovery of MEN 15442, an antagonist with subnanomolar affinity for the human B2 receptor (hB2R), which also displayed significant and prolonged activity in vivo (for up to 210 min) against BK-induced bronchoconstriction in the guinea-pig at a dose of 300 nmol/kg (it), while demonstrating only a slight effect on BK-induced hypotension. Here we describe the further optimization of this series of compounds aimed at maximizing the effect on bronchoconstriction and minimizing the effect on hypotension, with a view to developing topically delivered drugs for airway diseases. The work led to the discovery of MEN 16132, a compound which, after intratracheal or aerosol administration, inhibited, in a dose-dependent manner, BK-induced bronchoconstricton in the airways, while showing minimal systemic activity. This compound was selected as a preclinical candidate for the topical treatment of airway diseases involving kinin B2 receptor stimulation.